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Background  1 
Ovarian Cancer (OC) has the highest mortality rate of all gynaecological cancers, 2 
and is the fourth leading cause of cancer-related death among women. 3 
Approximately 20% of patients present with early stage disease and have a good 4 
prognosis. 70-80% of patients with advanced OC respond to primary therapy 5 
consisting of primary or delayed debulking surgery followed by platinum based 6 
combination chemotherapy, but have a >75% risk of recurrence, in most cases 7 
within three years, with two years median survival thereafter [1]. These patients have 8 
a short progression free interval and periods of remission of ever-shorter duration as 9 
tumours become increasingly resistant to chemotherapy. Many patients with 10 
recurrent disease have no or few symptoms at first but in later stages of the disease 11 
symptom burden is often heavy. On recurrence the aim of therapy shifts from cure to 12 
long term palliation to improve quality of life.  13 
The European Society of Medical Oncology recommends follow-up every three 14 
months for two years, every four months during the third year, and every six months 15 
during years four and five or until progression. The guideline states that at each 16 
appointment a doctor takes a clinical history and performs a physical examination 17 
including pelvic examination [2], together with measurement of the serum cancer 18 
antigen 125 (CA 125) tumour marker.  Guidelines indicate a CT scan if there is 19 
clinical evidence of progressive disease. However, these recommendations are not 20 
supported by any evidence, except that CA125 can accurately predict tumour 21 
recurrence. A recent UK survey [3] revealed that follow-up practices varied with most 22 
centres using a standard hospital-based protocol of appointments for 5 years with 23 
routine tests for women with ovarian cancer. A minority utilised nurse-led or 24 
telephone follow-up. The assumption that earlier treatment on detecting recurrence 25 
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and before symptoms develop would improve survival has been discredited by the 26 
MRC OV05/EORTC trial [4], which compared immediate treatment on the basis of 27 
increased CA125 concentrations versus waiting until clinical/symptomatic relapse 28 
and showed no difference in survival between the two arms.  29 
 30 
Randomised studies are lacking on most aspects of OC follow-up care [5]. Although 31 
hospital follow-up provides opportunities for managing the disease or treatment 32 
related symptoms and optimal referral to supportive and palliative care with Clinical 33 
Nurse Specialist (CNS) involvement, clinic appointments may lead to stress and 34 
delay [6]. Urgent research has been advocated not only to develop better predictors 35 
of treatment response and indicators of treatment benefit to inform treatment plans 36 
[7], but also to determine the most appropriate provision of follow-up care [8]. Such 37 
care may have to be flexible in order to take into account fear of recurrence [9], 38 
multiple treatments and associated decision-making [10]; symptom burden [11], and 39 
new treatments that may become available for relapsed OC where earlier 40 
intervention may be indicated [5]. This study of follow-up strategies directed towards 41 
quality of life and psychological impact in addition to cost-effectiveness pre-empts 42 
the recommendation of the recent almost “empty” Cochrane review of different types 43 
of follow-up in this patient group.   44 
 45 
 46 
Methods 47 
We conducted a prospective preliminary RCT of individually tailored follow-up 48 
(henceforth synonymously termed individualised or intervention treatment) led by a 49 
gynaecological CNS versus conventional follow-up in 3 gynaecological cancer 50 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
centres at one metropolitan and two suburban sites, comparing cost and effects on 51 
quality of life, mood and patient satisfaction. We followed MRC guidelines for the 52 
design and testing of complex interventions [12].  53 
Patients were consecutively approached and 113 patients (63% of 180 approached) 54 
were recruited into a follow-up period of two years.  Inclusion criteria were: clinical 55 
diagnosis of OC or fallopian tube or peritoneal cancer; completed primary treatment 56 
by surgery alone or with chemotherapy irrespective of outcome with regard to 57 
remission; expected survival > 3 months; aged >18 years; and willingness and ability 58 
to participate.  Relapse and recurrence dates, death, contacts with nurses and other 59 
members of the clinical team, reasons for contacts, clinic appointments, symptoms 60 
reported and hospital in-patient episodes were collected and recorded on a ‘Patient 61 
Events’ data base. The East London Research Ethics Committee approved the study 62 
(Trial registration number ISRCTN59149551) and a trial management group acted 63 
as adviser.  64 
After informed written consent was obtained, participants were randomly allocated to 65 
receive either individual follow-up (N= 57) or conventional follow-up (N= 56) [11]. 66 
Recruitment by centre was as follows: Centre 1 - Intervention N = 33, Conventional 67 
N= 30, Total 63; Centre 2 - Intervention N = 19, Conventional N= 20, Total 39; 68 
Centre 3 – Intervention N = 5, Conventional N = 5, Total 10. We considered random 69 
allocation for every individual participant, but given the small sample size we could 70 
have easily ended up with a disproportionate number in one arm purely by chance. 71 
For purposes of independent randomisation, we divided participants into those 72 
recruited at the metropolitan centre 1 and those at the suburban centres 2 & 3 with 73 
participants in each group randomly allocated to either conventional or individualised 74 
follow-up in a 1:1 ratio.  We allocated the first participant of a pair to one of the 75 
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follow-up groups using randomness derived from atmospheric noise 76 
(http://www.random.org).  We allocated the remaining participant to the other group. 77 
We found later that one patient randomised to conventional follow-up was ineligible 78 
and was excluded from the study: this left 112 patients for analysis. Figure 1 shows a 79 
participant Flow-Chart.  80 
 81 
Study measures 82 
We administered three validated self-report instruments at baseline, 3, 6, 12, 18 and 83 
24 months.  84 
Quality of life 85 
The European Organisation for Research and Treatment of Cancer [14] core QoL 86 
questionnaire (QLQ-C30) consists of 30-items questionnaire assessing 8 domains, 87 
and a number of specific symptoms as well as the perceived financial impact of the 88 
disease and treatment. We used the core scale with the site-specific OC module Ov-89 
28 [15] which consists of 28 items.  Higher scores for functioning subscales indicated 90 
better functioning; higher scores in symptom subscales indicated worse symptoms. 91 
Mood 92 
We used the 14-item self-rated Hospital Anxiety and Depression Scale (HADS) for 93 
use in the medically ill [16].  94 
Patient satisfaction 95 
 96 
We used the Ware Patient Satisfaction Questionnaire (PSQ-III) to measure patients’ 97 
perceptions of care [17] providing a summary measure of general satisfaction along 98 
with six aspects of health care.  99 
Use of services 100 
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We extracted data from the ‘Patient Events ‘ data base for the following types of 101 
service use during the two-year follow-up period: clinic appointments with the CNS; 102 
CNS visits while the patient was an inpatient; telephone consultations with the CNS; 103 
email consultations with the CNS; clinic appointments with the consultant 104 
gynaecological oncologist; clinical appointment with other types of consultant; clinic 105 
appointment with clinical psychologist; clinic appointment with complementary 106 
medicine team; inpatient stays. We also recorded primary care contacts and reasons 107 
by questionnaire to general practitioners. 108 
 109 
Procedures 110 
Conventional Arm 111 
Follow-up of asymptomatic patients consisted of one post-treatment outpatient 112 
appointment with further appointments at three monthly intervals including complete 113 
clinical history and CA 125 and radiological imaging when symptoms or signs 114 
appeared. The doctor and other members of the clinical team including nurse 115 
specialists not otherwise involved in the study also saw patients based on need.  116 
 117 
Intervention Arm 118 
We allocated patients selected for individualised follow-up to one of several 119 
gynaecological cancer nurse specialists at participating hospitals. They met with the 120 
nurse immediately after their end of treatment appointment to negotiate follow-up to 121 
suit their individual situation. Contact was flexible, primarily by telephone at 122 
prearranged mutually convenient times, although some women opted for face-to-123 
face appointments, usually at the regular gynaecological cancer clinic. In addition, 124 
contact with the nurse was made when necessary in the regular gynaecological 125 
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oncology clinic or by telephone without prearranged appointment. Patients were 126 
assessed using a holistic guide to identify signs of disease progression, symptoms 127 
warranting intervention, and psychological issues.  Unless the patient had worsening 128 
symptoms needing further treatment, the nurse was responsible for the care of 129 
patients receiving individualised follow-up. The nurse would discuss with the 130 
patient’s consultant and arrange any necessary investigations, for example a CT 131 
scan before a clinic appointment with the doctor. The four nurses delivering the 132 
intervention were expert in the management of OC, having completed generic 133 
cancer nursing and specialist gynaecological cancer nurse training; they were 134 
cognisant of post treatment surveillance dilemmas and “watchful waiting” for 135 
patients, including patients’ preoccupation with CA 125 levels. The intervention was 136 
informed by a model of health promoting interactions [18] oriented towards improving 137 
self-efficacy [19]. In addition, nurses were familiarised with the concept of adjustment 138 
to cancer described by Brennan [20] in two workshops designed to prepare them for 139 
their role in the study. The nurses provided information and support to assist patients 140 
to manage troublesome symptoms and live with the psychological discomfort of 141 
enduring uncertainty. Adherence to the intervention treatment protocol was 142 
supported by the study protocol and the preparation and ongoing support of the 143 
nurses. One or two CNSs in each of the three sites not trained in the intervention 144 
approach provided care in the conventional arm. The researcher (AL) was engaged 145 
at each study site to encourage trained CNSs not to share the specific approach with 146 
their colleagues during the study.  147 
 148 
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Statistical analysis 151 
Questionnaire items were organised into functional domains: 13 functional domains 152 
in QLQ-C30, 7 in QLQ-OV28, 7 in PSQ-III and the HADS domain. They were 153 
additively combined (with appropriate signs) within each of the 28 functional 154 
domains to form corresponding functional scores measuring discomfort on a 0-100 155 
scale, and within each of the 4 questionnaires to form four corresponding global 156 
scores measuring discomfort on a 0-100 scale.  Each (functional or global) score 157 
was separately modelled to depend on tumour stage (STAGE), on the current 158 
number of days spent by the patient under the intervention treatment (DAYS OF 159 
INTERVENTION, defined to be uniformly zero in the conventional treatment arm), on 160 
her age at randomisation (AGE) and on her current number of days since 161 
randomisation (TIME), allowing for quadratic AGE and TIME relationships. The 162 
model for each score also contained a pair of patient-specific - a priori correlated - 163 
random effects to allow the intercept and linear trend component of each patient's 164 
trajectory to deviate from average. By modelling the random intercepts to be 165 
unaffected by treatment we incorporated the assumption that the treatment has no 166 
baseline effect. Primary study outcomes were the effect of treatment on each global 167 
score, measured by the corresponding estimated regression coefficient of DAYS OF 168 
INTERVENTION, and the effect of treatment on the hazard of relapse, as estimated 169 
via Cox's regression adjusting for the patient's age and tumour stage. 170 
Of secondary interest was the breakdown of treatment effect according to the 28 171 
functional scores. 172 
 173 
Economic analysis 174 
We calculated the total cost of follow-up for each patient multiplying service use by 175 
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unit costs obtained from 2011/12 NHS Reference Costs [21] and summing across all 176 
types of use. We compared unadjusted service use and total costs between each 177 
group using Mann-Whitney two-sample statistics. We analysed differences in 178 
medians because the data were highly skewed. In adjusted analyses we regressed 179 
total costs per patient against treatment controlling for age at baseline (cubic 180 
function), disease stage and grade at baseline, and study site. We used a 181 
generalised linear model with gamma family and log link [22]. We adjusted for 182 
clustering by participant and calculated the marginal effect of individualised follow-up 183 
compared with conventional follow-up. 184 
 185 
Results 186 
Mean age of participants in the intervention arm was 62 years (range 23-92) whilst in 187 
the conventional arm the mean was 61 years (range 21-85). Clinical and 188 
demographic characteristics of participants are presented in Table 1.  189 
 190 
At baseline there was no significant treatment effect on the global QLQ-C30 191 
score (p-value = 0.3), global QLQ-OV28 score (0.34), global PSQ III score (0.4) or 192 
global HAD score (0.3). The main analysis was based on 112 patients. 193 
 194 
Table 2 shows the estimated fixed effects for the global QLQ-C30 score (see table 195 
caption for an explanation of the content). The estimated effect of the individualised 196 
treatment, adjusted for tumour stage and age at randomisation, was −0.016, 197 
corresponding to an expected decrease in discomfort of 5.76 points per year with 198 
respect to the conventional treatment. This represents statistically significant (two-199 
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tailed test p-value=0.013) evidence of a beneficial advantage of the individualised 200 
treatment according to QLQ-C30. 201 
 202 
Table 3 shows the estimated effects of the individualised treatment on each of the 13 203 
QLQ-C30 functional scores, relative to the conventional treatment, adjusting for 204 
tumour stage and patient's age. The sign of all but one t-statistics indicates a uniform 205 
beneficial advantage of the individualised treatment, four of these statistics achieving 206 
two-tailed 5 percent statistical significance. Insufficient data information at a 207 
functional score level may explain the non-significant estimate for the effect of 208 
diarrhoea, whose 95% confidence interval is nevertheless compatible with the 209 
hypothesis that the individualised treatment is beneficial also in terms of this item. 210 
 211 
The results from our analysis of the global QLQ-OV28 score are shown in Table 4. 212 
These data indicate only modest and non-significant evidence in favour of the 213 
individualised follow-up, after adjusting for tumour stage and patient’s age. The 214 
estimated coefficient of DAYS OF INTERVENTION is −0.0027 (two-tailed p-215 
value=0.14).  216 
 217 
A bayesian noninferiority analysis of these data can be used to further explore this 218 
finding. A bayesian analysis of the same data, based on a locally uniform prior for 219 
the model parameters, yields a bayesian 95 percent posterior credible interval of (-220 
0.002, 0.005) for the coefficient of DAYS OF INTERVENTION. This corresponds to a 221 
95 percent credible interval of (-0.6, 1.5) for the yearly increase in QLQ-OV28 global 222 
score attributable to the intervention treatment. We may take this to indicate that - in 223 
the worst scenario and excluding extremely unlikely events - the intervention 224 
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treatment will be responsible for a 0.6 yearly increase of the QLQ-OV28 global 225 
score, with respect to what would have been obtained via conventional treatment. 226 
The median value for the QLQ-OV28 score at one year from randomisation is about 227 
37. We may thus interpret the data as suggesting that, if we allow for a very small 228 
margin of tolerance, the individualised treatment is non-inferior to the conventional 229 
one in terms of their impact on QLQ-OV28 quality of life. 230 
 231 
Supplemental Table 1, indicates that there was no significant benefit of one 232 
treatment over the other in terms of global HAD score, either marginally or after 233 
adjusting for the effects of tumour stage and patient’s age. In this analysis the effect 234 
of the individualised treatment gave a t-statistic of 0.221, which fails to achieve the 235 
required statistical significance level, and the corresponding 95% confidence interval 236 
spans a region of clinically negligible effect. 237 
 238 
Table 5 reports the results from the fitting of our hierarchical mixed-effects model to 239 
the global PSQ-III score data. The estimated regression coefficient for DAYS OF 240 
INTERVENTION, adjusted for tumour stage and age at randomisation, represents 241 
significant evidence (two-tailed test p-value=0.002; 95% confidence interval -0.03 242 
through -0.001) of a benefit of the individualised treatment over the conventional 243 
one in terms of PSQ-III. Supplemental Table 2 compares the effects of the two 244 
treatments on each of the five PSQ-III functional scores.  245 
 246 
Effects on PSQ-III functional scores 247 
We compared the two treatments in terms of their effects on the following five PSQ-248 
III functional scores: general satisfaction (based on 6 items), interpersonal aspects (7 249 
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items), communication (5 items), time spent with health care professional (2 items) 250 
and access/ availability/convenience (12 items). High values of these functional 251 
scores indicate “high satisfaction”. The results from fitting a mixed model to each of 252 
these functional scores are reported in Supplemental Table 2. For 253 
each functional score, the table reports the estimated coefficient of DAYS OF 254 
INTERVENTION, as a measure of the effect of the individualised treatment relative 255 
to the conventional one, its standard error, the corresponding t-statistic and the 95% 256 
confidence interval. The t-statistic for each item except “Communication” provides 257 
stronger that 5 percent significant evidence that there is a beneficial advantage of 258 
the individualised treatment over the conventional one in terms of PSQ-III. The 259 
results for “Communication” provide fair (albeit short of 5 percent significance) 260 
evidence that the individualised treatment is superior also in terms of this particular 261 
item. 262 
 263 
Effect of the intervention on the relapse-free time 264 
The effect of treatment on relapse-free time was assessed via Cox’s model, taking 265 
time from randomization as the main temporal scale, and adjusting for patient’s age 266 
and tumour stage.  Included in the model was an interaction between the 267 
intervention treatment and tumour stage. The results from fitting the model under an 268 
assumption of proportional hazards are summarised by Supplemental Table 3. For 269 
each unknown parameter, the table reports the estimated coefficient in the 270 
regression (COEF), its exponentiated value (relative risk), its standard error, the Z- 271 
statistic, the p-value for the null hypothesis of no effect and the 95 272 
percent confidence interval for exp (COEF). The table shows modest evidence of a 273 
dependence of the risk of relapse on patient's age at randomization, and borderline-274 
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significant evidence of an interaction between treatment and tumour stage.  The 275 
sign and the Z-statistic for the intervention treatment effect represent some evidence 276 
(albeit short of nominal statistical significance) that the individualised treatment tends 277 
to reduce the risk of (and hence to delay) the relapse, at least in a non-advanced 278 
stage of the tumour.  This effect appears to be moderated by an advanced stage of 279 
the tumour. 280 
 281 
Cost analysis 282 
In individualised follow-up patients had significantly fewer clinic appointments with 283 
the consultant gynaecological oncologist and more clinic appointments, telephone 284 
consultations and email consultations with the CNS (all p <0.01; Supplemental Table 285 
4). There were no significant differences in other types of service use. Cost data 286 
were highly skewed (Supplemental Fig 1 and Table 5): patients in the nurse-led 287 
follow-up group had significantly lower costs in unadjusted analyses (p <0.01; 288 
Supplemental Table 4). In adjusted analyses costs were £700 lower on average for 289 
the nurse-led follow-up group, but the difference was not statistically significant at the 290 
5% level (p = 0.07; Supplemental Table 6).  291 
 292 
Dealing with missing data in economic analysis 293 
Data on primary care contacts were missing for 39 (35%) patients, 24 patients in the 294 
conventional follow-up group (44%) and 15 in the nurse-led follow-up group (26%). 295 
We imputed missing data for both types of primary care contact (GP visits, practice 296 
nurse visits) simultaneously using multiple imputation by chained equations. 297 
Prediction equations were estimated using negative binomial regression since the 298 
variables with missing data were over dispersed count variables. The imputation 299 
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models included age at baseline (cubic function), disease stage and grade at 300 
baseline, study site, and numbers of clinic appointments with the CNS, CNS visits 301 
while the patient was an inpatient, telephone consultations with the CNS, email 302 
consultations with the CNS, clinic appointments with the consultant gynaecologist 303 
oncologist, clinical appointment with other types of consultant, clinic appointment 304 
with clinical psychologist, clinic appointment with complementary medicine team, 305 
inpatient stays, and total costs. Values were imputed 20 times; we re-estimated the 306 
models using alternative random number seeds and obtained similar results. The 307 
imputed data were used to create a new total cost variable including GP and practice 308 
nurse visits for all participants and the impact of nurse-led follow-up compared with 309 
conventional follow-up was analysed using a generalised linear model with gamma 310 
family and log link adjusting for clustering by participant. Coefficients and standard 311 
errors were computed accounting for the variability between imputations using the 312 
combination rules by Rubin [23].  313 
 314 
Discussion  315 
The findings of this preliminary study provide a foundation for further research of 316 
individually tailored models of follow-up care in OC. The individualised treatment 317 
offers an advantage over conventional follow-up in terms of the QoL aspects 318 
represented in QLQ-C30 and in PSQ-III, and is equivalent to conventional treatment 319 
for mood represented in HADS. It is also desirable as regards relapse free time and 320 
symptomatic reporting of relapse.  321 
 322 
For effective communication it has been argued that patient and clinician must share 323 
a common representation or model of the condition [24]. If patients represent their 324 
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OC illness and symptom experience differently from the clinician managing their 325 
care, they may become disaffected with the service and doubt the quality of its 326 
clinical decision-making and treatment, thereby delaying the implementation of an 327 
effective treatment plan. Leventhal’s theory may explain the overall QoL benefit in 328 
the individualised group, confirming our hypothesis that nurses would develop close 329 
knowledge of individual patients and collaborate with them to relieve their symptoms, 330 
alleviate their distress and help their adjustment to an uncertain future. The regular 331 
surveillance focus of the conventional arm, with less continuity of medical personnel 332 
and arguably less time for patients to discuss their recovery, symptoms or fears of 333 
recurrence, may have caused greater dissonance than the intervention group [25].  334 
 335 
In the study we considered the practical issues of implementation for example: trial 336 
procedures including the willingness of medical staff to recruit patients; the 337 
willingness of eligible participants to be randomised; examination of potential 338 
adverse effects of the intervention; performance of a basic economic analysis to 339 
inform a larger trial; and assessment of the overall acceptability of the intervention.  340 
Despite a commitment to enrol consecutive patients more patients than we 341 
anticipated were deemed unsuitable for the study by their consultant and some were 342 
simply judged too sick with multiple co-morbidities. This is an important finding as it 343 
highlights a potential limitation to individualised follow-up programmes in OC. 344 
Characteristics of patients who were not offered enrolment in this study will form the 345 
basis of a future paper exploring barriers to individualised follow-up schemes.  346 
 347 
Other limitations of this preliminary work may have influenced our results.  No pre-348 
defined criteria were used to establish whether the follow-up model warranted 349 
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progression to a larger RCT study. It is a recognised challenge in intervention 350 
studies that aspects of the intervention cannot be controlled and usual methods of 351 
avoiding bias when applied are likely to have partial success. Patients’ expectations 352 
of continuity and responsiveness are a potential a source of bias. Nurses trained to 353 
deliver the intervention are likely to be invested in its success and consequently they 354 
may have made a special effort to be attentive and fulfil patients’ expectations of 355 
continuity and responsiveness to their difficulties. The two-year period of follow-up 356 
and involvement of four nurses across three study sites may have offset these 357 
effects.  358 
 359 
In a future work we plan to study the role of post-randomization processes (nurse 360 
reaction to emotional challenge [26] and compliance with protocol [27]) and 361 
mediating variables (number of contacts) in the treatment mechanism), for a better 362 
understanding of how the individualised treatment works, and for a fuller assessment 363 
of the evidence in its favour. This will involve the use of causal inference "analysis of 364 
mediation" methods [28]. These data might identify nurse skills as one cause – and 365 
therapeutic alliance as a main mediator – of the benefits of individualised treatment. 366 
Analysis of the data along these lines might (1) produce statistically more significant 367 
results in favour of the individualised treatment, (ii) allow us to identify early 368 
predictors of treatment outcome, (iii) provide compelling evidence of the need to 369 
develop the conditions for nurses to be able to engage patients.   370 
 371 
The UK National Cancer Survivorship Initiative has outlined plans for improved care 372 
of those living with and after cancer [29], including pathways of follow-up care based 373 
on risk of recurrence and late effects [30]. Setting up an evidence-based framework 374 
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of effective new care models must be a priority [31] and prospective studies are 375 
needed to evaluate the quality of life issues and psychological impact of different 376 
follow-up approaches in addition to investigating survival outcomes and cost-377 
effectiveness. Interventions are likely to include nurse-led, telephone and patient initiated 378 
follow-up and the relative merits of these strategies should be prospectively evaluated.  379 
 380 
These preliminary results highlight the effect on outcome of the quality and focus of 381 
the nurse-patient relationship and the need for training and support to deliver flexible 382 
individualised follow-up. OC incidence is stable but OC mortality rates are predicted 383 
to fall by over 40% (42.6%) to 5 deaths per 1,000 women by 2030 [32] as therapy 384 
improves. The increasingly chronic nature of OC with more use of targeted and 385 
maintenance treatments, makes it important to assess the value women place on 386 
QoL as part of long-term survivorship assessment and to provide models of care that 387 
are respectful of individual patient choice and which educate and support women in 388 
the surveillance of their disease and management of their symptoms.  389 
 390 
This pilot trial provides evidence to suggest that an individualised approach to OC 391 
follow up can improve quality of life and delay diagnosis of relapse in a cost effective 392 
protocol. This approach requires validation in further studies and if confirmed could 393 
be an important development in OC care in the UK NHS and other healthcare 394 
systems.  395 
 396 
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Figure and table legends 480 
Figure 1: Patient participant flow chart 481 
Table 1: Clinical and demographic characteristics of participants.  482 
Table 2: Estimated fixed effects of our mixed effects regression model for the 483 
dependence of the global QLQ-C30 score on tumour stage, days since 484 
randomisation (TIME), age at randomisation (AGE) and days of intervention 485 
treatment.  486 
Table 3: This table reports the estimated effect of the individualised treatment on 487 
each of the functional QLQ-C30 scores, in terms of score increase produced by one 488 
day of individualised treatment with respect to the conventional one. 489 
Table 4: Analysis of the effect of the intervention treatment on the global QLQ-OV28 490 
score. 491 
Table 5: Analysis of the effect of the individualised treatment on the global PSQ-III 492 
score measuring  493 
 "lack of" satisfaction.  494 
 495 
Supplementary Digital Content 496 
Table 1: Analysis of the effect of the intervention on global HAD score. (Word file) 497 
Table 2: Analysis of the effect of fitting the mixed model to each of the PSQ III 498 
functional scores separately. (Word file) 499 
Table 3: Results from the fitting of Cox's proportional hazards model of 500 
the dependence of relapse-free time on treatment, adjusting for age at randomisation 501 
and tumour Stage. (Word file) 502 
Table 4. Use of services and total cost per patient. (Word file) 503 
Figure 1. Distribution of total cost per person in each group. (TIFF file) 504 
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Table 5. Unit costs. (Word file)  505 
Table 6. Adjusted analysis of nurse-led follow-up on total costs.  (Word file)  506 
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Figure 1
 Intervention 
treatment 
Conventiona
l treatment 
Overall 
Stage at diagnosis       
Borderline 2 2 4 
I - Ic 25 18 43 
II - IIc 5 6 11 
III - IIIc 22 25 47 
IV 3 4 7 
ECOG performance status at randomisation       
0 = Fully active, able to carry on all predisease performance without restriction 35 31 66 
1 = Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature  
15 14 29 
2 = Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about more than 50% of waking hours 6 7 13 
3 = Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours 
1 2 3 
4 = Completely disabled. Cannot carry on any selfcare. Totally confined to bed or 
chair 1 0 1 
Co-exisiting diseases         
Cardiovascular diseases & hypertension 3 2 4 
Cerebrovascular disease 2 1 3 
Respiratory disorders 1 2 3 
Diabetes without end-organ damage (excludes diet-controlled alone) 1 1 2 
Osteoporosis 3 1 4 
Obesity  4 4 8 
Endocrine, nutritional & metabolic disorders 1 0 1 
Digestive system disorders 5 5 10 
Autoimmune diseases 1 0 1 
Renal disease 1 0 1 
Ethnicity       
White - British 48 42 90 
White - Irish 3 4 7 
White - other background 4 5 9 
Asian  2 1 3 
Black or black British 1 1 2 
Chinese 0 1 1 
Marital status       
Single 3 3 6 
Married/Living with partner 31 37 68 
Divorced/Separated 9 9 18 
Widow 11 9 20 
Employment Status       
Employed full time (including on sick leave) 18 21 39 
Employed part time 14 16 30 
Unemployed 3 3 6 
Home-maker 9 11 20 
Retired 8 9 17 
Highest education level       
Less than compulsory school education 5 2 7 
Compulsory school education 33 34 67 
Post compulsory school education - below university 15 16 31 
Post compulsory school education - university level 5 2 7 
Table 1
Table 1 
The clinical and demographic characteristics of participants.  
Tables 2-5  
 
 
 
Parameter Estimate Standard error t-value 95% confidence interval 
Intercept 78.75 29.6 2.66  
Tumour stage 0.79 0.49 1.58 -0.17, 1.75 
Time 0.032 0.013 -2.41 0.006, 0.057 
Time2 0.000051 0.000012 4.06 0.000031, 0.00007 
Age at randomisation 0.005 0.0028 -1.79 -0.00049, 0.01 
Age2 0.00000012 0.000000064 1.96                       -5.44 ×10^-9, 2.4 ×10^-7   
Days of intervention treatment -0.016 0.0074 -2.22 -0.03, -0.001 
  
Table 2: Estimated fixed effects of our mixed effects regression model for the dependence of the global 
QLQ-C30 score on tumour stage, days since randomisation (TIME), age at randomisation (AGE) and 
days of intervention treatment.  
These estimates have been obtained assuming that the score depends on TIME and AGE through a quadratic (or, 
as a case, linear) relationship. Dependence on DAYS OF INTERVENTION has been assumed to be linear. For 
each estimated parameter, this table reports point estimate, standard error, corresponding t-statistic and 95% 
confidence interval. Of inferential interest is the coefficient of DAYS OF INTERVENTION, representing the 
expected increase in QLQ-C30 discomfort produced by one day of individualised treatment with respect to that 
produced by one day of conventional treatment. According to this table, the sign and the magnitude of the 
estimate of this coefficient represent 5 percent  significant evidence of a beneficial advantage of the 
individualised treatment over the conventional one (two-tailed p-value = 0.013, 95% confidence interval -0.03 
through -0.001). 
 
 
  
Table 2-5
 
 
 
Functional score Estimate x 100 Standard error t-value 95% confidence interval 
Physical -2.14 0.016 -1.28                                             -0.052, 0.009 
Role -4.65 0.022 -2.09   -0.003, -0.089 
Emotion -1.95 0.014 -1.39                                            -0.046,  0.007 
Social -3.93 0.019 -2.02  -0.076, -0.002 
Global -7.66 0.033 -2.29 -0.141, -0.011 
Fatigue -2.28 0.018 -1.27 -0.058, 0.012 
Nausea/vomiting -0.18 0.009 -0.18 -0.019, 0.015 
Pain -2.83 0.018 -1.53 -0.063, 0.006 
Dyspnoea -1.12 0.019 -0.61 -0.048, 0.026 
Sleep -1.58 0.021 -0.73 -1.954, 0.025 
Appetite loss -4.34 0.015 -2.82 -0.072, -0.014 
Constipation -2.99 0.017 -0.17 -0.063, 0.003 
Diarrhoea 0.8 0.011 0.68 -0.013, 0.029 
  
Table 3: This table reports the estimated effect of the individualised treatment on each of the functional 
QLQ-C30 scores, in terms of score increase produced by one day of individualised treatment with respect 
to the conventional one.  
For each effect, the table reports the point estimate, the standard error, the t-statistic and the corresponding 95% 
confidence interval. These estimates are valid under the mixed effects model described in the Statistical Analysis 
section. 
 
  
  
Parameter Estimate Standard error t-value 95% confidence interval 
(Intercept) 55.2 4 13.62  
Stage 0.77 0.2 3.88 0.378, 1.162 
Time -0.014 0.0053 -2.64 -0.024, -0.003 
Time2 0.000012 0.000005 2.29 2.2 x 10^-6, 2.18 x 10^-5 
Age 0.00074 0.00017 -4.30 4 x 10^-4, 0.001 
Days of Intervention -0.0027 0.0026 -1.06 -0.007, 0.002 
  
Table 4: Analysis of the effect of the intervention treatment on the global QLQ-OV28 score.  
For an explanation of table content see caption of Table 3. The  sign of the estimated coefficient of DAYS OF 
INTERVENTION points to a beneficial advantage of the individualised treatment over the conventional one in 
terms of QLQ-OV28 quality of life, although the estimate fails to achieve 5 percent statistical significance (two-
sided test p-value = 0.14). 
 
 
  
 
 
 
 
Parameter Estimate Standard error t-value 95% confidence interval 
(Intercept) -12.78 5.9  -2.16 - 
Stage 0.97 0.3 0.32 -0.48, 0.68 
Time 0.005 0.0026  2.02  -0.003, 0.021 
Time2 -3.88×10^-6  6.1-10^-6 -0.63  -1.59×10^-5, 8.13×10^-6 
Age -0.00032 0.00026 -1.25  -0.0008, 0.00018 
Days of intervention -0.009 0.0032  -2.8  -0.015, -0.003 
 
Table 5: Analysis of the effect of the individualised treatment on the global PSQ-III score measuring  
 "lack of" satisfaction.  
For an explanation of table content see caption of Table 3. The magnitude and the sign of the estimated 
coefficient of DAYS OF INTERVENTION represent statistically very significant evidence of a beneficial 
advantage of the intervention treatment compared to the conventional one (two-tailed p-value=0.002). 
 
 
 
 
 
Supplementary Digital Content 
   
 
Parameter Estimate Standard error t-value 95% confidence interval 
(Intercept) -10.53 5.66 -1.862                                                                     -  
Stage 0.12 0.095 -1.307 -0.066,  0.3 
Time 0.00089 0.0026  0.336 -0.004, 0.005 
Time2 0.0000016 0.0000026 -0.597 -3.5 ×10^-6, 6.7 ×10^-6 
Age 0.000067 0.00054 0.124 -9.9 ×10^-4, 0.001 
Days of intervention 0.00029  0.0013         0.221 -1.85 x 10^-8, 2.85 ×10^-8 
  
SDC Table1: Analysis of the effect of the intervention on global HAD score 
For an explanation of the content of this table see caption of Table 3. The effect of the intervention treatment on 
the HAD global score, adjusted for tumour stage     and  age at randomisation, is represented in this table by the 
coefficient of DAYS OF INTERVENTION. The results in this table contain no evidence of an effect of the 
intervention treatment on global HAD score. 
 
 
 
 
Functional score Estimate * 1000 St error *1000 t-value 95% confidence interval 
General satisfaction -2.25     0.85 -2.64 -3.9, -0.58 
Interpersonal relationships -2.53 0.86 -2.9 -4.2, -0.8 
Communication -0.85 0.58 -1.46 -1.98, 0.28 
Time -1.04 0.37 -2.76 -1.76, -0.31 
Accessibility -2.26 1.09 -2.07 -4.39, -0.12 
 
 
SDC Table 2: Analysis of the effect of fitting the mixed model to each of the PSQ III functional scores 
separately.   
For each score, the table reports the estimated coefficient, which measures the effect of the intervention, its 
standard error and the corresponding t-statistic and confidence intervals. The t-statistic for each item except 
Communication lies in the 5 percent region indicating that there is an effect and the coefficients are all negative 
indicating beneficial effect of the intervention arm. 
 
 
Parameters Coef Exp(coef) Standard error for Coef z-statistic p-value 95% confidence interval for Coef 
Age 0.00008 1 0.000047 1.72 0.08 (0.99, 1) 
Tumour stage 0.19 1.21 0.083 2.3 0.021 (1.03, 1.43)  
Intervention 
treatment 
-4.8 0.008 2.88 -1.677 0.09 (0.000027, 2.26) 
Stage x 
intervention 
0.4 1.5 0.24 1.68 0.08                                             (1.03, 2.44) 
 
  
SDC Table 3: Results from the fitting of Cox's proportional hazards model of the dependence of relapse-
free time on treatment, adjusting for age at randomisation and tumour Stage.  
For each unknown parameter, the table reports the estimated coefficient in the regression (COEF), its 
exponentiated (relative risk) value, its standard error, the Z statistic and the p-value for the null hypothesis of no 
effect and the corresponding 95 percent confidence interval. 
 
Additional tables
  
 
 
  
                  
  Conventional follow-up (n=55)*   Nurse-led follow-up (n=57)*    
  Mean (SD) Median (IQR)   Mean (SD) Median (IQR) P value† Unit cost‡ 
Clinic appointment with clinical nurse specialist 0.3 (1.0) 0 (0 to 0)  4.1 (3.1) 3 (2 to 7) <0.01 95 
Clinical nurse specialist visits patient in hospital 0.1 (0.3) 0 (0 to 0)  0.1 (0.4) 0 (0 to 0) 0.22 95 
Telephone consultation with clinical nurse specialist 0.7 (1.3) 0 (0 to 1)  6.8 (8.4) 4 (2 to 9) <0.01 40 
Email consultation with clinical nurse specialist 0 (0) 0 (0 to 0)  1.6 (4.5) 0 (0 to 0) <0.01 40 
Clinic appointment with consultant gynaecological oncologist 10.7 (7.2) 7 (6 to 18)  3.5 (4.7) 2 (0 to 4) <0.01 191 
Clinic appointment with other type of consultant 0.5  (1.1) 0 (0 to 0)  0.5 (1.6) 0 (0 to 0) 0.16 111 
Clinic appointment with clinical psychologist 0.5 (2.1) 0 (0 to 0)  0.5 (1.8) 0 (0 to 0) 0.56 137 
Clinic appointment with complementary medicine team 0.2 (0.8) 0 (0 to 0)  0.6 (1.9) 0 (0 to 0) 0.49 95 
Inpatient stay 0.5 (1.3) 0 (0 to 0)  0.5 (1.4) 0 (0 to 0) 0.87 1987 
Visit GP at practice  5.4 (6.6) 2 (1 to 9)  3.6 (3.9) 2.5 (0 to 5) 0.27 43 
Visit practice nurse at GP practice  0.9 (2.6) 0 (0 to 1)  0.7 (2.0) 0 (0 to 0) 0.62 14 
Total cost (excluding GP and practice nurse visits) 3266 (3355) 1806 (1146 to 4664)   2620 (3621) 991 (745 to 2999) <0.01  
Total cost (including GP and practice nurse visits) 3775 (3691) 2620 (1272 to 5424)  2943 (3963) 1270 (904 to 3466) 0.06  
SD = standard deviation. IQR = interquartile range. * For GP visits, practice nurse visits and total cost including GP and practice nurse visits, due to missing data the number of observations in the conventional follow-
up group was n=31 and in the nurse-led follow-up group it was n=42. † Calculated using Mann-Whitney two-sample statistic. ‡ Calculated in 2011/12 UK£. See web extra material for further details.  
 
 SDC Table 4. Use of services and total cost per patient  
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Tests for normality on combined data: Shapiro–Wilk normality test: P <0.01.  
 
 SDC Figure 1. Distribution of total cost per person in each group  
 
 
 
  
 
Cost component Unit cost* Notes 
Clinic appointment with CNS 95 Specialist Palliative Care: Outpatient. Non-Medical Specialist Palliative Care Attendance, 19 years and over. 
CNS visits patient in hospital 95 Specialist Palliative Care: Outpatient. Non-Medical Specialist Palliative Care Attendance, 19 years and over. 
Telephone consultation with CNS 40 Non-Consultant Led: Follow up Attendance Multiprofessional Non-Admitted Non Face to Face. Medical oncology. 
Email consultation with CNS 40 Non-Consultant Led: Follow up Attendance Multiprofessional Non-Admitted Non Face to Face. Medical oncology. 
Clinic appointment with consultant gynaecological oncologist 191 Specialist Palliative Care: Outpatient. Medical Specialist Palliative Care Attendance, 19 years and over. 
Clinic appointment with other type of consultant 111 Consultant Led: Follow up Attendance Non-Admitted Face to Face. Weighted mean across all attendances. 
Clinic appointment with clinical psychologist 137 Non-Consultant Led: Follow up Attendance Multiprofessional Non-Admitted Face to Face. Clinical psychology. 
Clinic appointment with complementary medicine team 95 Specialist Palliative Care: Outpatient. Non-Medical Specialist Palliative Care Attendance, 19 years and over. 
Inpatient stay 1987 Total - HRGs. Gynaecological Malignancy with length of stay 0 days and Gynaecological Malignancy with length of stay 1 day or 
more. Weighted mean across all admissions. 
 
SDC Table 5. Unit costs   
All figures taken from National Schedule of Reference Costs 2011/12*. Calculated in 2011/12 UK£. 
* Department of Health. National Schedule of Reference Costs - Year 2011-12 - NHS trusts and NHS foundation trusts: NHS own costs. Department of Health: London, 2012. 
https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 [last accessed 13 September 2013]. 
 
 
 
 
 
 Marginal effect SE Z score P value 95% CI 
Total cost (excluding GP and practice nurse visits) -695 394 -1.8 0.07 -1467 to 77 
Total cost (including GP and practice nurse visits) -745 409 -1.8 0.08 -1546 to 56 
 
SDC Table 6. Adjusted analysis of nurse-led follow-up on total costs   
Controls are included for age at baseline, disease stage at baseline, disease grade at baseline and study site. The analysis excluding GP and practice nurse visits was based on 
complete cases; the analysis including these visits used imputed data (Online supplementary material). The marginal effect is the mean difference in total costs between the 
two groups adjusting for the controls. SE = standard error. CI = confidence interval. 
 
